Why Does the Buyer Care? Diligence Risks in Behavioral Health M&A

Revenue Durability

What Makes Revenue Worth Paying For

A buyer pays for revenue it expects to repeat and discounts anything that looks fragile. That is why diligence teams break revenue down by service line, payer, location, and provider. Recurring, in-network revenue from an established patient base is worth more than episodic, cash-pay, or marketing-dependent volume, even when the dollars look identical on the income statement. Owners who can show that breakdown cleanly, month by month, earn credibility before the first management meeting.

Growth faces that test as well. Strong year-over-year growth supports a higher multiple, but only if the buyer believes it will continue. Equity investors want to know whether growth came from new clinicians, new locations, rate increases, or a temporary spike in demand. Lenders press harder, because they size debt against trailing EBITDA and need confidence those earnings will last. Growth that traces back to one new contract, one productive hire, or a one-time reimbursement change will be treated as less bankable than steady, broad-based growth with capacity left to fill.

Why Buyers Discount Payer and Referral Concentration

When a single payer represents 30 or 40 percent of revenue, the buyer is effectively betting on that payer's future behavior. A rate cut, a narrowed network, or a new medical necessity policy can move EBITDA overnight. Buyers will read the contracts themselves, looking for unilateral rate-reduction rights, termination without cause, short notice periods, and anti-assignment language. Buyers will model a downside case for the largest payer, and a payer mix spread across commercial and Medicaid plans, or long-dated contracts with favorable terms, keeps that scenario from moving the price.

Out-of-network and nonstandard reimbursement draw closer scrutiny still. Most buyers today prefer the predictability of in-network contracts, and they know payers can tighten out-of-network policies at any time. Revenue built on single-case agreements or unusually high rates will usually be normalized down to in-network levels in the buyer's projections or moved into an earnout.  

Referral concentration carries a parallel risk. Many behavioral health practices depend on a small number of relationships, such as a hospital system, a handful of physicians, a school district, or a single treatment center. If one source drives a disproportionate share of new patients, the buyer will ask what happens the day that relationship ends. A diversified referral base, with relationships that belong to the organization rather than to one person, shows the buyer that patient flow can survive the loss of any one source.

The People Who Generate the Revenue

People are the core input across behavioral health, but how revenue depends on them varies by level of care. In outpatient mental health, psychiatry, and ABA, revenue is tied directly to individual clinicians and can leave with them. In residential, partial hospitalization (PHP), and intensive outpatient (IOP) programs, revenue follows census, but census is capped by the licensed staff a program can keep on the floor and the ratios its license and accreditation require. In both settings, buyers evaluate the team as carefully as the financials. In founder-led organizations, the owner is often the top producer, the primary referral relationship, and the person payers know by name. Buyers will measure how much revenue depends on the owner personally, and high dependence leads to longer transition commitments, larger rollover requirements, or earnouts tied to the owner's continued production.

Team stability is the other variable, and buyers price it through retention. Expect questions about clinician tenure, turnover, use of agency staff and contractors, and compensation relative to market, followed by requests for retention agreements with key clinicians before closing. Revenue tied to contractors or to clinicians with incomplete credentialing files gets discounted in the valuation.

Buyers usually address these risks through structure, shifting value into earnouts, rollover, and longer transitions. That moves part of the price from closing day into the years after it. Diversifying payers and referral sources, documenting the drivers behind growth, and building clinical leadership beyond the owner all take time, which is why that work needs to start well before a sale process does.

Billing and Compliance Exposure

Could Collected Revenue Be Taken Back?

Revenue durability asks whether cash will keep coming in. Compliance exposure asks whether cash already collected might have to be paid back. In behavioral health, the second question often carries more weight, and it is where deals most often get repriced or fall apart.

Billing Hygiene, Coding Accuracy, and Modifiers

Most buyers will commission a coding and billing audit that samples claims across providers and service lines. They are checking whether the documentation supports what was billed, whether time-based psychotherapy codes match the session notes, and whether evaluation and management (E/M) levels are consistent with the record. Systematic upcoding or thin documentation implies an overpayment liability that reaches back across the full lookback period.

Modifiers are among the most common sources of findings because they change how a claim gets paid. Typical problems include modifiers used to unbundle services that should be billed together or appended to visits that do not qualify for separate payment, telehealth modifiers and place-of-service codes that do not match how care was delivered, and supervision or provider-type modifiers that are missing or misapplied. Each sub-vertical has its own pressure points:

• Psychiatry: E/M visits paired with psychotherapy add-on codes, where psychotherapy time must be documented separately from the E/M service
• ABA: units billed compared with session notes, and whether board certified behavior analyst (BCBA) supervision of registered behavior technicians (RBTs) meets payer requirements
• Substance use treatment: urine drug testing frequency and level-of-care documentation

A pattern of modifier errors is one of the fastest ways for a small audit sample to become an extrapolated liability.

Denials Tell the Story Before the Audit Does

Denial history shows what payers have already flagged. High or rising denial rates, frequent medical necessity denials, and large write-offs can point to credentialing gaps, front-end eligibility problems, or coding issues. Buyers will break denials down by payer and reason code and look at how often appeals succeed. A clean, well-managed denial history is some of the best evidence an owner can offer that the billing operation is under control.

Credentialing Lapses Become Recoupment Exposure

If a clinician saw patients while a license, payer enrollment, or supervision arrangement was lapsed or incomplete, the claims for those services may not have been payable at all. That turns what feels like an administrative oversight into a repayment obligation. This is especially common in group practices that rely on associate-level therapists billing under supervision, and in ABA programs with high RBT turnover. Buyers will match every rendering provider against licensure and enrollment dates, so it is far better for the owner to find those problems first.

Clawbacks Follow the Business After Closing

Medicare, Medicaid, and commercial payers can all audit and recoup payments years after the service was delivered. Medicare and Medicaid overpayments must also be reported and returned within 60 days of identification, and False Claims Act exposure can reach back six years, or up to 10 in some cases. Audits by the HHS Office of Inspector General have identified nearly $200 million in improper Medicaid ABA payments across four states since late 2024, which is why buyers in that space now evaluate compliance as closely as growth. No buyer wants to inherit those claims, so they protect themselves through escrows, holdbacks, and specific indemnities for known issues, which representation and warranty insurance excludes. The more exposure a buyer finds, the more of the seller's proceeds end up held back at closing.

Referral Practices and Anti-Kickback Exposure

Buyers will look closely at how the practice generates patients and how it pays anyone connected to referrals. Marketing arrangements, medical director agreements, space and equipment leases with referral sources, and patient inducements all fall under the federal Anti-Kickback Statute and its state counterparts. In substance use treatment, state patient brokering laws and the federal Eliminating Kickbacks in Recovery Act, which also covers commercially insured patients, add another layer of scrutiny. Arrangements that are written, priced at fair market value, and tied to legitimate services withstand review. Informal ones become specific indemnities or reasons for a buyer to walk away.

Investigations and Privacy

Any subpoena, civil investigative demand, payer audit, board complaint, or whistleblower matter will be disclosed and dissected. Prior issues are rarely deal-breakers on their own, but undisclosed ones almost always are.

Privacy and cybersecurity draw a similar review. Behavioral health records are among the most sensitive data in healthcare, and buyers will ask for HIPAA risk assessments, policies, business associate agreements, breach history, and details on electronic health record (EHR) security. Substance use treatment providers will also be asked about compliance with 42 CFR Part 2, which governs those records separately from HIPAA. A past incident that was handled and reported properly is manageable. An environment that has never been assessed is a liability the buyer has to price.

A pre-sale compliance assessment lets an owner identify these issues before going to market and resolve them through corrective action and, where needed, voluntary repayment. A resolved issue costs the seller far less at the negotiating table than an open liability.

Financial Presentation

Add-Backs Only Count If They Survive the Quality of Earnings Review

Adjusted EBITDA sets the purchase price, and the deal multiple magnifies every dollar of adjustment. Buyers typically test each add-back through a third-party quality of earnings (QoE) review, from owner compensation to related-party rent and other common normalizations. Documented, nonrecurring adjustments stand. Recurring costs labeled as one-time, or revenue from unsigned contracts, come out.

A practical rule I share with clients: If an add-back cannot be backed by invoices, payroll records, or a clear explanation of why it will not recur under new ownership, assume the buyer will reject it.

Working Capital and the Cash Behind the EBITDA

Most deals are priced on a cash-free, debt-free basis, with a normalized level of working capital, known as the peg, delivered at closing. In behavioral health, accounts receivable (A/R) is usually the largest piece of working capital, so how buyers value A/R drives much of that negotiation. Buyers will look at days in A/R, aging, collection rates by payer, and how much of the receivable balance is realistically collectible. Aged or doubtful receivables typically get reserved against, which lowers the working capital delivered at closing, and slow collections push the peg higher. Either result reduces the effective price.

The core issue is whether reported EBITDA reliably turns into cash in the bank. Clean cash conversion supports both valuation and lender appetite, and it is one of the clearest signals that the earnings on paper are genuine.

Transferability

A Practice Is Only as Valuable as Its Ability to Bill on Day One

A behavioral health organization's value rests on the licenses, enrollments, and contracts that allow it to deliver and bill for care. If those do not transfer cleanly, the buyer may close on a business that cannot get paid for months. That is why buyers map every state license, facility certification, accreditation, payer contract, and provider enrollment, and work out what happens to each one at closing.

Some of those transfer automatically in an equity purchase. Others require notice, consent, or new filings:

• Medicare and Medicaid: change of ownership filings
• Commercial payer contracts: consent under anti-assignment or change-of-control clauses
• State licenses for behavioral health and substance use programs: new applications and, often, inspections
• Opioid treatment programs: DEA registrations and Substance Abuse and Mental Health Services Administration (SAMHSA) certification
• Spravato sites: Risk Evaluation and Mitigation Strategy (REMS) certification

Any delay in those approvals means a stretch of time where services may not be reimbursable, which buyers handle through closing conditions, delayed closings, or interim management arrangements. Owners can shorten that timeline by inventorying all licenses, enrollments, and contracts ahead of time and flagging which ones will need consent.

What the Buyer Inherits

Deal structure determines how much of the seller's history comes along. In a stock or equity purchase, the buyer acquires the entity with everything attached to it: past billing errors, tax issues, employment claims, pending disputes, and any open investigations. In an asset purchase, the buyer can leave many of those liabilities behind. Medicare-certified facilities, such as psychiatric hospitals and community mental health centers offering partial hospitalization, are the exception: A buyer that accepts assignment of the seller's Medicare provider agreement to keep billing without interruption also takes on the overpayment liability tied to that agreement. Buyers prefer asset deals for this reason, while sellers often push for equity deals, partly for tax treatment, and the difference usually resolves through price, indemnification caps, escrows, and insurance.

Either way, the buyer is pricing your history along with your future, and the cleaner that history is, the less of the purchase price goes to protecting against it.

Final Thoughts

Buyers care about these risks because each one touches either the cash flow they are paying for or the liabilities they might inherit. The best time to find a diligence problem is before the buyer does. Issues an owner discovers can be fixed, explained, or disclosed on the owner's terms. Issues a buyer discovers become leverage. For most behavioral health owners, finding them first means a third-party coding and billing audit, a credentialing reconciliation, a sell-side QoE, and an inventory of what needs consent to transfer.

Owners planning to sell in the next few years have the most room to act now, before a buyer's diligence team starts asking. VERTESS works with behavioral health owners to surface these issues before a sale process begins, from recasting earnings to reconciling credentialing and payer data, so diligence confirms the value already in the business. Start with our M&A Readiness Questionnaire to see where you stand, then contact us to discuss what a buyer is likely to focus on in your business.